Spero Therapeutics files $100 million at-the-market shelf with Jefferies, closes Cantor agreement unused
Small-cap biotech equity issuance has run tactical rather than wholesale against the backdrop of a cost-of-capital environment that has kept the discount rate visible across the sector. On August 28, 2026, Spero Therapeutics…
Key takeaways
- On August 28, 2026, Spero Therapeutics (Nasdaq: SPRO) filed an 8-K disclosing a new Open Market Sale Agreement with Jefferies LLC to raise up to $100 million in common stock via at-the-market transactions.
- The Jefferies facility replaces a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald that had been in place since March 11, 2021, which was terminated effective August 28, 2026 with no termination penalties.
- Spero sold no shares under the $75 million Cantor agreement across fiscal years 2024 and 2025, leaving it unused over its five years of access.
- The $100 million Jefferies tranche sits within a broader $300 million universal shelf Registration Statement on Form S-3 that is not yet effective, meaning no shares can be sold until the SEC declares it effective.
- Jefferies will act as agent with no obligation to sell a fixed quantity of stock, earning compensation of up to 3.0% of gross proceeds on shares actually sold.
Small-cap biotech equity issuance has run tactical rather than wholesale against the backdrop of a cost-of-capital environment that has kept the discount rate visible across the sector. On August 28, 2026, Spero Therapeutics (Nasdaq: SPRO) filed an 8-K with the SEC disclosing a new Open Market Sale Agreement with Jefferies LLC, through which the Cambridge, Massachusetts company may raise up to $100 million in common stock through at-the-market transactions. The Registration Statement on Form S-3 covering the offering is not yet effective, and no shares may be sold until the SEC declares it so.
A facility replaced after years unused
The Jefferies arrangement replaces a Controlled Equity Offering Sales Agreement that Spero had maintained with Cantor Fitzgerald and Co. since March 11, 2021. That prior facility carried capacity of up to $75 million and was terminated effective August 28, 2026, with no termination penalties to the company. Across fiscal years 2024 and 2025, Spero had sold no shares under the Cantor agreement. Over five years of access, nothing drawn.
The $100 million Jefferies tranche sits within a broader universal shelf Registration Statement, also filed on August 28, 2026. That shelf covers up to $300 million in aggregate, spanning common stock, preferred stock, debt securities, depositary shares, subscription rights, units, and warrants. Under the Sale Agreement, Jefferies will act as agent and is under no obligation to sell any fixed quantity of stock; its compensation will be up to 3.0% of the gross proceeds on shares actually sold. Esther Rajavelu, Chief Executive Officer of Spero Therapeutics, signed the filing.
The read-through for the broader cycle is limited but the structure tells a story. A company that carried a $75 million equity facility for over five years without once using it, then filed a larger $100 million shelf at a moment when even that shelf has yet to be declared effective, is building optionality into the balance sheet rather than flagging near-term dilution. In a discount-rate environment that has kept biotech valuations compressed sector-wide, the timing question the filing leaves open is the one that matters.
Related reading
Source · 來源